Drug Profile


Alternative Names: Goserelin acetate implant; Zoladex

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Prostate cancer; Uterine haemorrhage

Most Recent Events

  • 20 Feb 2017 AstraZeneca and TerSera enter into commercialisation agreement of goserelin in USA and Canada (9211708; 9211781)
  • 15 Mar 2016 Biomarkers information updated
  • 29 Feb 2012 AstraZeneca completes a phase III trial in Endometriosis (adjuvant therapy) in China (NCT00938496)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top